Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test plus symptom check may spare thousands from celiac biopsy

NCT ID NCT07701655

Not yet recruiting Diagnosis Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study aims to see if a blood test for TTG-IgA antibodies combined with symptom information can accurately sort adults into low, intermediate, or high risk for celiac disease. Researchers will analyze data from 15,500 patients who already had both a blood test and a duodenal biopsy. If the model works, people at low risk could avoid further testing, those at high risk might skip biopsy, and only intermediate-risk patients would need the invasive procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could replace many invasive biopsies with a simple blood test and questionnaire, making celiac diagnosis faster and less uncomfortable.
What could go wrong
The model may not be accurate enough to safely skip biopsies in all cases, and results from this large observational study need validation before changing practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELIAC DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.